Fed. Circ. Upholds Preliminary Injunction On Biaxin XL

Law360 (October 21, 2008, 12:00 AM EDT) -- Echoing its earlier decision upholding a preliminary injunction in a suit over patents for Abbott Laboratories' antibacterial drug Biaxin XL, a federal appeals court ruled Tuesday that Sandoz Inc. could not start marketing its generic version before the resolution of the patent trial between the two companies.

The U.S. Court of Appeals for the Federal Circuit's decision to let stand the April 2007 preliminary injunction granted by the U.S. District Court for the Northern District of Illinois relied on the Federal Circuit's January 2007 decision against...
To view the full article, register now.